Eli Lilly: FDA authorizes antibody therapy for Covid-19

(CercleFinance.com) - The Food and Drug Administration has authorized the use of Lilly's antibody therapy for the treatment of recently diagnosed Covid-19 patients.


The agency's action, called an emergency-use authorization, permits use of the treatment in mild-to-moderate forms of the virus in high-risk patients, Lilly said.

The drugmaker's neutralizing antibody, called bamlanivimab, has been designed to block viral attachment and entry into human cells, thus neutralizing the virus.

Lilly scientists have developed the antibody in under three months, after it was discovered by Canadian biotech firm AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.

The therapy was developed thanks to a blood sample taken from one of the first US patients who recovered from Covid.

Copyright (c) 2020 CercleFinance.com. All rights reserved.